003220.KS
Daewon Pharmaceutical Co., Ltd.
KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 7,700.00
−0.77%Year over year
Reported trailing growth
- Revenue
- +1.9%
- EBITDA
- —
- EBIT
- —
- EPS
- -67.9%
- Free cash flow
- -91.9%
- Operating cash flow
- -68.6%
Forward estimates
Based on analyst estimates
- Revenue
- -71.7%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +8.1%
- EBITDA
- -23.9%
- EBIT
- -56.7%
- Net income
- —
- EPS
- —
- Free cash flow
- -11.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026